ERBB2 and breast carcinoma: Our national breast cancer management guideline does not recommend HER2 testing as a part of standard evaluation protocol in breast cancers.29 This is consistent with the core level of resource-stratified guidelines for LMIC, which includes basic cancer medicines and basic hormonal therapies only.